Journal
METABOLITES
Volume 11, Issue 12, Pages -Publisher
MDPI
DOI: 10.3390/metabo11120847
Keywords
breath analysis; metabolomics; COVID-19; GCxGC-MS; noninvasive analysis
Categories
Funding
- MIUR
Ask authors/readers for more resources
Researchers used metabolomics analysis of exhaled breath condensate to discover potential biomarkers for noninvasive diagnosis and monitoring of COVID-19. They found that fatty acids in EBC can differentiate COVID-19 patients and may have a protective effect, suggesting their potential use as a preventive strategy against the infection.
Infection from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can lead to severe respiratory tract damage and acute lung injury. Therefore, it is crucial to study breath-associated biofluids not only to investigate the breath's biochemical changes caused by SARS-CoV-2 infection, but also to discover potential biomarkers for the development of new diagnostic tools. In the present study, we performed an untargeted metabolomics approach using a bidimensional gas chromatography mass spectrometer (GCxGC-TOFMS) on exhaled breath condensate (EBC) from COVID-19 patients and negative healthy subjects to identify new potential biomarkers for the noninvasive diagnosis and monitoring of the COVID-19 disease. The EBC analysis was further performed in patients with acute or acute-on-chronic cardiopulmonary edema (CPE) to assess the reliability of the identified biomarkers. Our findings demonstrated that an abundance of EBC fatty acids can be used to discriminate COVID-19 patients and that they may have a protective effect, thus suggesting their potential use as a preventive strategy against the infection.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available